Precigen (PGEN) Other Non Operating Income (2012 - 2026)
Precigen (PGEN) posted quarterly Other Non Operating Income of $290000.0 for Q1 2026, up 4042.86% year-over-year from $7000.0 in Q1 2025, and up 383.33% quarter-over-quarter from $60000.0 in Q4 2025.
Powered by 
Analysis
Precigen (PGEN) Other Non Operating Income (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Other Non Operating Income for 15 consecutive years, with $290000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 4042.86% year-over-year to $290000.0; the TTM figure through Mar 2026 stood at $326000.0 (down 94.14% YoY), while the FY2025 annual figure was $43000.0, down 99.23% from the prior year.
- Other Non Operating Income rose to $290000.0 in Q1 2026 per PGEN's latest filing, from $60000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $8.5 million in Q4 2024 and bottomed at -$3.0 million in Q3 2024.
- Historically, Other Non Operating Income has averaged $476117.6 across 5 years, with a median of $44000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 13250.0% — and 2024, when it sank 1162.28%.
- Precigen's Other Non Operating Income stood at $263000.0 in 2022, then plunged by 129.66% to -$78000.0 in 2023, then soared by 10997.44% to $8.5 million in 2024, then slumped by 99.29% to $60000.0 in 2025, then jumped by 383.33% to $290000.0 in 2026.
- Business Quant data shows PGEN's Other Non Operating Income at $290000.0 in Q1 2026, $60000.0 in Q4 2025, and $7000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | 290,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | 8.50 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Jun 30, 2024 | 43,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | -78,000.00 |
| Sep 30, 2023 | 281,000.00 |
| Jun 30, 2023 | 44,000.00 |
| Mar 31, 2023 | 380,000.00 |
| Dec 31, 2022 | 263,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 40,000.00 |
| Mar 31, 2022 | 198,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -133,000.00 |